US Capitol Capsule: Biomedical innovation: This stuff is hard
This article was originally published in Scrip
After decades of pursuing drug development in much the same way, one thing the biopharmaceutical industry has learned is "this stuff is hard" and it oftentimes has been a rough road going it alone, said Dr Mark McClellan, a senior fellow and director of the Health Care Innovation and Value Initiative at the Washington-based think tank the Brookings Institution.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.